In NSCLC patients with a TMB equivalent to or greater than 10 mut/Mb, the combination of ipilimumab and nivolumab compared to chemotherapy was reported to have a better overall response (OR) and PFS, regardless of PD-L1 expression [47, 48]. Here, CD274 is linked to non-small cell lung carcinoma.